Vermont Center on Behavior and Health, Department of Psychiatry, University of Vermont, 1 South Prospect St. Rm 1415, Burlington, VT, 05403, USA.
Westat, Rockville, MD, USA.
J Gen Intern Med. 2017 Sep;32(9):974-980. doi: 10.1007/s11606-017-4062-6. Epub 2017 May 3.
Disparities in tobacco use are worsening in the United States, disproportionately affecting those with chronic medical conditions. One possible contributor is that physicians may not screen and advise cessation uniformly across patients and/or tobacco products.
This study examined provider communications regarding cigarette and non-cigarette tobacco products among adults with chronic conditions.
Cross-sectional study drawn from two waves (2013-2014) of the National Survey on Drug Use and Health (NSDUH).
Adults (≥ 18 years) who used tobacco in the past year.
Prevalence of tobacco use included past-year use of cigarettes, cigars, or smokeless tobacco among those with and without chronic conditions. Chronic conditions included asthma, anxiety, coronary heart disease, depression, diabetes, hepatitis, HIV, hypertension, lung cancer, stroke, and substance abuse. Odds ratio of receipt of screening and advice to quit across chronic condition and tobacco product type were reported. Data were analyzed using logistic regression, controlling for basic sociodemographic factors and number of provider visits.
Adults with anxiety, depression, and substance use disorders had the highest prevalence of past-year cigarette (37.2-58.2%), cigar (9.1-28.0%), and smokeless tobacco (3.1-11.7%) use. Patients with any chronic condition were more likely to receive advice to quit than those without a condition (OR 1.21-2.37, p < 0.01), although the odds were lowest among adults with mental health and substance use disorders (OR 1.21-1.35, p < 0.01). Cigarette smokers were more likely to report being screened and advised to quit than non-cigarette tobacco users (OR 1.54-5.71, p < 0.01).
Results support the need for provider training to expand screening and cessation interventions to include the growing spectrum of tobacco products. Screening and referral to interventions are especially needed for those with mental health and substance use disorders to reduce the disparate burden of tobacco-related disease and death.
在美国,烟草使用方面的差异正在加剧,对患有慢性疾病的人群的影响尤为严重。一个可能的原因是医生可能没有在患者和/或烟草产品之间统一进行筛查和戒烟建议。
本研究检查了在患有慢性疾病的成年人中,医生在香烟和非香烟烟草产品方面的沟通情况。
横断面研究,来自国家药物使用和健康调查(NSDUH)的两个波次(2013-2014 年)。
过去一年中使用过烟草的成年人(≥ 18 岁)。
过去一年中,包括有和没有慢性疾病的成年人使用香烟、雪茄或无烟烟草的情况。慢性疾病包括哮喘、焦虑、冠心病、抑郁、糖尿病、肝炎、HIV、高血压、肺癌、中风和物质滥用。报告了在慢性疾病和烟草产品类型方面接受筛查和戒烟建议的几率。数据通过逻辑回归进行分析,控制了基本的社会人口因素和就诊次数。
患有焦虑症、抑郁症和物质使用障碍的成年人过去一年中使用香烟(37.2%-58.2%)、雪茄(9.1%-28.0%)和无烟烟草(3.1%-11.7%)的比例最高。有任何慢性疾病的患者比没有疾病的患者更有可能接受戒烟建议(比值比 1.21-2.37,p<0.01),尽管心理健康和物质使用障碍患者的几率最低(比值比 1.21-1.35,p<0.01)。与非香烟烟草使用者相比,香烟吸烟者更有可能报告接受了筛查和戒烟建议(比值比 1.54-5.71,p<0.01)。
结果支持对医生进行培训的需求,以扩大筛查和戒烟干预措施,包括日益多样化的烟草产品。对于心理健康和物质使用障碍患者,特别需要进行筛查和转介干预,以减少烟草相关疾病和死亡的巨大差异负担。